Satellos Bioscience Inc. has designated SAT-3153 as a development candidate for Duchenne muscular dystrophy and will move the candidate into pre-IND-enabling studies and toward an IND filing. SAT-3153 is a small molecule designed to inhibit a particular kinase protein which the company believes controls Notch polarity within muscle stem cells.